Phreesia Swings To Q3 Profit, Revises FY26 Outlook, Issues FY27 Guidance

Phreesia posted a Q3 FY2026 profit of $4.27 million ($0.07/sh) versus a year-ago loss, with revenue rising 13% to $120.33 million and adjusted EBITDA improving to $29.15 million from $9.77 million; revenue per AHSC increased about 6% to $26,622 and AHSC counts are rising. For FY2026 the company narrowed revenue guidance to $479m–$481m (from $472m–$482m) and materially raised adjusted EBITDA guidance to $99m–$101m (from $87m–$92m), and it provided a FY2027 outlook of $545m–$559m revenue and $125m–$135m adjusted EBITDA, with AHSC and revenue-per-AHSC expected to grow mid-single and low-double digits, respectively. The results and upgraded EBITDA targets point to improving operating leverage driven by volume and monetization gains, while shares were essentially flat, closing at $20.12 (down 0.84%).

Analysis

Phreesia reported a clear operational improvement in Q3 FY2026, turning a year-ago net loss of $14.40 million ($0.25/share) into net income of $4.27 million ($0.07/share) while adjusted EBITDA rose to $29.15 million from $9.77 million and total revenue increased 13% to $120.33 million from $106.80 million. Revenue per AHSC rose about 6% to $26,622 from $25,207, indicating monetization gains at the customer-unit level concurrent with topline growth.

For fiscal 2026 management narrowed revenue guidance to $479 million–$481 million (from $472M–$482M) while materially raising adjusted EBITDA guidance to $99 million–$101 million (from $87M–$92M), and raised AHSC expectations modestly to ~4,515 from ~4,500 (4,203 in FY2025). The company provided a FY2027 bridge of $545M–$559M revenue and $125M–$135M adjusted EBITDA, with AHSC mid-single-digit growth and revenue-per-AHSC growing low-double digits.

The guidance mix—conservative revenue band but significantly higher EBITDA—signals improving operating leverage and margin expansion driven by higher monetization and scale, yet the modest AHSC lift and only a small share-price reaction (closed $20.12, down 0.84%) imply investor caution about execution. Key risks are execution on AHSC growth and sustaining revenue-per-AHSC acceleration; failure to meet FY2027 cadence would undermine the upgraded EBITDA trajectory.

Key Decisions for Investors

• Consider a constructive bias (buy or add) given the profit turnaround and materially raised FY2026 adjusted EBITDA guide, but size positions modestly pending confirmation of AHSC and revenue-per-AHSC trends
• Monitor next two quarterly updates for AHSC count, revenue per AHSC and adjusted EBITDA delivery as primary catalysts and trim exposure if growth or monetization stalls relative to the FY2027 path
• If holding material exposure, consider partial hedging or staged position increases tied to demonstrable execution on the FY2026 guide and the initial FY2027 quarterly cadence